RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.comIdentafi™ 3000's Optical Spectroscopy Profiled At Oral Oncology 2nd World Congress in Toronto - Two Texas Scientists Who Developed "Multispectral" Technology Participate in Presentations on Its Use in Diagnosis of Oral Cancer
TORONTO, August 26, 2009 — Two Houston scientists who helped develop the breakthrough optical technology for cancer early detection called "multispectral" spectroscopy were among the contributors who delivered oral cancer research presentations at the recent Second World Congress of the International Academy of Oral Oncology (IAOO).
"Multispectral" Technology Highlighted
"Oral Oncology: Imagine the Future" (www.iaoo2009.com/index.htm) was the theme of the conference, which was held July 8-11 at the Sheraton Centre Toronto Hotel.
Dr. Rebecca Richards-Kortum of the Optical Spectroscopy and Imaging Laboratory at Rice University in Houston and Dr. Ann M. Gillenwater of the Head and Neck Surgery and Epidemiology Department at The University of Texas M.D. Anderson Cancer Center in Houston were members of the team that delivered an IAOO presentation titled "Depth-Sensitive Optical Spectroscopy for Diagnosis of Oral Neoplasia."
Gillenwater and Richards-Kortum collaborated with other researchers in another presentation, titled "Autofluorescence Imaging for Early Detection of Oral Neoplasia."
Gillenwater also participated in two other presentations at the IAOO conference titled, respectively, "Depth-Sensitive Optical Spectroscopy for Diagnosis of Oral Neoplasia" and "Autofluorescence Imaging for Early Detection of Oral Neoplasia."
Gillenwater is Director of M.D. Anderson's Oral Cancer Prevention Center. Her research focuses on the detection and treatment of early oral cancer and pre-cancer, including Merkel cell carcinoma (MCC).
Richards-Kortum is the Stanley C. Moore Professor of Bioengineering, Chair of the Bioengineering Department, and Professor of Electrical and Computer Engineering at Rice University. Her research centers on new, noninvasive cancer detection technologies that use high-resolution, optical imaging; the use of fluorescent imaging agents for cancer detection; biophysical studies of the light-scattering properties of cells and tissues; and the use of fiber optic sensors for in vivo detection of cancer.
Richards-Kortum is one of the founding scientists of Trimira, LLC, which is a subsidiary of Remicalm LLC, a privately held Houston medical device and optical imaging company. Trimira is the maker of Identafi™ 3000, the only high-powered, handheld device for screening dental patients to reveal signs of oral cancer and pre-cancer.
Another Trimira founding scientist, Dr. Calum MacAulay, participated in the IAOO conference presentation titled "Image Cytometry for Oral Cancer Screening."
MacAulay is the Head of the Cancer Imaging Department, British Columbia Cancer Research Centre in Vancouver, Canada. MacAulay is also a Clinical Associate Professor in the Department of Pathology and an Associate Member of the Physics Department at the University of British Columbia.
Identafi Is Only Device to Use "Multispectral" Technology
Created exclusively for intraoral use, the small cordless Identafi™ 3000 unit is ergonomically shaped for dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians. The industry-leading device incorporates next-generation oral cancer-detection optical reflectance and fluorescence technology, which is changing the screening and diagnostic landscape for the nation's dentists and doctors.
Identafi™ 3000
Identafi™ 3000 is the only device on the market that illuminates with three wavelengths of brilliant white, violet, and green-amber light. This patented feature minimizes false positives and reveals abnormalities in oral tissue missed by the naked eye. Unlike other methods, Identafi™ 3000 empowers doctors and dentists to pinpoint biochemical and morphological changes in cells. It represents a quantum leap in the visualization of oral cancer or premalignant dysplasia. The multispectral technology not only is effective in screening oral cancers but also in diagnosing cervical, skin, gastrointestinal, and bladder cancers.
About Trimira™ LLC
Trimira LLC is venture capital-funded by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit Trimira™ at: http://www.trimira.net
Animations
Identafi® Technology
Identafi® 3000 ultra Process
Screening Results
Training
